Kurl D N, Stjernquist-Desatnik A, Schalén C, Christensen P
Acta Pathol Microbiol Immunol Scand B. 1985 Dec;93(6):401-5. doi: 10.1111/j.1699-0463.1985.tb02909.x.
The possibility of inducing immunity in the upper respiratory tract against type M50 group A streptococci was studied in mice. The M50 type exhibited an LD100 a of 10(5) colony-forming units (CFU) when administered intranasally (i.n.), and of 10(7) CFU when introduced intraperitoneally (i.p.). I.n. administered vaccines prepared from M types 12, 18, 30, 49, 50 and 55 were equally efficient in preventing lethal infection after i.n. challenge with type M50. Subcutaneous (s.c.) immunization with type 18 had no effect, whereas s.c. immunization with type 50 was effective against i.n. challenge with type 50. Neither with i.n. nor s.c., did vaccination with type 18 - in contrast to with type 50 - protect against i.p. challenge with type 50. The results strongly suggest that local immunity against M50 group A streptococci can be achieved using a non-type-specific mechanism. Once the local barrier had been overcome, protection against systemic infection was type-specific in accordance with classic concepts.
在小鼠中研究了在上呼吸道诱导针对M50型A组链球菌免疫的可能性。M50型经鼻内（i.n.）给药时的半数致死剂量（LD100）为10⁵集落形成单位（CFU），经腹腔内（i.p.）给药时为10⁷CFU。用M12、18、30、49、50和55型制备的经鼻内给药疫苗在经鼻内用M50型攻击后预防致死性感染方面同样有效。用18型进行皮下（s.c.）免疫无效，而用50型进行皮下免疫对经鼻内用50型攻击有效。与50型不同，无论是经鼻内还是皮下，用18型疫苗接种均不能预防经腹腔内用50型攻击。结果强烈表明，可使用非型特异性机制实现针对M50型A组链球菌的局部免疫。一旦局部屏障被突破，根据经典概念，针对全身感染的保护是型特异性的。
